Get additional insights from deeper analysis of key data readouts Access detailed summaries of key data releases and Oncofocus' views on these outcomes Get details on your next sessions (like location, time, presenter, etc.) with ease

Quickly access details of your high-priority sessions for a particular day in a tabular format

Compare the new data against the existing benchmarks Observe competitive shift after certain key data releases Get a recap of current benchmarks in charts Understand if there were any press releases or previous data on a particular study Access schedules and studies of interest to you Here's how it can support you before, during, and after a conference: #asco23 #asco2023 #pharma #cancerresearch #oncology #novusai #oncofocusīelow is the explainer video on our Novus AI, an AI-powered conference intelligence platform that helps you maximize your conference experience from start to finish. What sets NovusAI apart is its ability to present these findings in a visually compelling format, making complex information easily understandable and actionable for Pharma executives, decision-makers, and stakeholders. This year, I am here with our Novus AI, an AI-powered conference intelligence platform that enables us to perform comprehensive analyses and extract valuable insights swiftly and efficiently. Each conference has been a treasure trove of knowledge and an opportunity for personal and professional growth. Throughout these years, I have had the privilege of meeting some of the brightest minds in the field, engaging in thought-provoking discussions, and witnessing groundbreaking advancements in cancer research and treatment. It's hard to believe that it has already been 10 incredible years since I embarked on my journey of attending medical conferences! As I stand here at ASCO 2023, I am filled with an overwhelming sense of excitement and gratitude for this remarkable milestone. #CAR-T #ImmunoACT #Celltherapy #IITBombay #lymphoma #leukemia #DCGI īreakthrough cancer treatment to be available in India 1st time as CAR-T cell therapy gets DCGI nod NexCAR19 was studied in Phase 1 and 2 trials conducted across various hospitals, including Tata Memorial Hospitals’ Advanced Centre for Treatment, Research and Education in Cancer in Mumbai, India, and a total of 60 patients, including both young adults and adults, underwent treatment.Īccording to ImmunoACT CEO Rahul Purwar, the therapy will soon be accessible in approximately 20 government and private hospitals in major cities in India. Notably, NexCAR19 significantly reduces the cost of therapy, with prices in India ranging from USD 36,000 to USD 42,000, as opposed to USD 399,000 in the US, making it much more affordable for patients in India. CAR-T therapy, a revolutionary treatment, has been approved in India! Developed by IIT-Bombay spin-off company ImmunoACT and its partner Laurus Labs, NexCAR19 is approved by DCGI for relapsed-refractory B-cell lymphoma and leukemia.

Keynote 590 fda